Drug Type Small molecule drug |
Synonyms ILB 2109, ILB2109, WTS-001 |
Target |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 25 Jul 2023 | |
Classical Hodgkin's Lymphoma | Phase 2 | CN | 25 Jul 2023 | |
Endometrial Carcinoma | Phase 2 | CN | 25 Jul 2023 | |
Melanoma | Phase 2 | CN | 25 Jul 2023 | |
Nasopharyngeal Carcinoma | Phase 2 | CN | 25 Jul 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | CN | 25 Jul 2023 | |
Ovarian Cancer | Phase 2 | CN | 25 Jul 2023 | |
Soft Tissue Sarcoma | Phase 2 | CN | 25 Jul 2023 | |
Triple Negative Breast Cancer | Phase 2 | CN | 25 Jul 2023 | |
Uterine Cervical Cancer | Phase 2 | CN | 25 Jul 2023 |